• Profile
Close

Fibroblast growth factor 23 and mortality in patients with type 2 diabetes and normal or mildly impaired kidney function

Diabetes Care Sep 17, 2019

Yeung SMH, Binnenmars SH, Gant CM, et al. - In patients with type 2 diabetes (T2D) and normal or mildly impaired kidney function, researchers investigated the link between fibroblast growth factor 23 (FGF23) and adverse outcomes. In 310 individuals with T2D and estimated glomerular filtration rate ≥ 60 mL/min/1.73 m2, COOH-terminal FGF23 levels were examined. According to results, 47 patients developed major adverse cardiovascular events, and 28 patients died during a follow-up of 5.8 years (3.3–6.5). Findings suggested an association of FGF23 with an increased risk of cardiovascular events and mortality in patients with T2D and normal or mildly impaired kidney function.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay